Floatz logo

Trastuzumab

Metastatic Malignant Neoplasm In The Brain

Iambic Therapeutics, Incmonoclonal_antibodyPhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
73/ 100

Competitive context

100 Active assets in the Metastatic Malignant Neoplasm In The Brain cohort.

Asset / SponsorPhaseRating
Icotinib
Betta Pharmaceuticals Co., Ltd.
Phase 3BB
Trastuzumab Deruxtecan
Baptist Health South Florida
Phase 4BB
Copper Cu 64-Dota-Trastuzumab
City of Hope Medical Center
Phase 4BB
Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3BB
Memantine
NRG Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Trastuzumab is also rated in:

breast carcinomaActive
BBB
Indicative · Phase 4
76 / 100
View asset →
inflammatory breast carcinomaActive
BBB
Indicative · Phase 3
74 / 100
View asset →
HER2 positive breast carcinomaActive
BB
Indicative · Phase 4
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →